|
Advances in drug life cycle management technology require
innovative approaches with specialized design, expanded functionality and greater
emphasis on time, cost and quality. We develop product platforms and fundamental
features which can be customized to meet the unique needs of our customers'
drug development programs.
AT-GC is developing products for
cancer
-Prostate Cancer
infectious diseases
- Hepatitis B, Dengue Fever, Malaria
multi
drug resistant infections - Tuberculosis
Staphylococcus infections- S. aureus infections
GI tract infections- Helicobacter pylori infections (peptic ulcer)
|
